prezista 75mg tablets
janssen-cilag ltd - darunavir ethanolate - tablet - 75mg
prezista 150mg tablets
janssen-cilag ltd - darunavir ethanolate - tablet - 150mg
prezista 100mgml oral suspension
janssen-cilag ltd - darunavir ethanolate - oral suspension - 100mg/1ml
prezista 800mg tablets
janssen-cilag ltd - darunavir ethanolate - tablet - 800mg
darunavir accord 600 mg film-coated tablets
accord healthcare ireland ltd. - darunavir - film-coated tablet - 600 milligram(s) - protease inhibitors; darunavir
darunavir accord 800 mg film-coated tablets
accord healthcare ireland ltd. - darunavir - film-coated tablet - 800 milligram(s) - protease inhibitors; darunavir
darunavir accord tablet, film coated 600mg
accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - darunavir propylene, glycolate - film-coated tablet - darunavir propylene glycolate 600 mg - antivirals for systemic use
edurant
j-c health care ltd - rilpivirine as hydrochloride - tablets - rilpivirine as hydrochloride 25 mg - rilpivirine - rilpivirine - edurant™, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naïve adult patients with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy.
edurant
janssen-cilag international n.v. - rilpivirine hydrochloride - hiv infections - antivirals for systemic use - edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection in antiretroviral treatment‑naïve patients 12 years of age and older with a viral load ≤ 100,000 hiv‑1 rna copies/ml. as with other antiretroviral medicinal products, genotypic resistance testing should guide the use of edurant.,
edurant 25mg tablets
janssen-cilag ltd - rilpivirine hydrochloride - tablet - 25mg